Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alexandra Castillo

Nurse Practitioner Hollywood, FL Nurse Practitioner

NPI 1639797426 CMS profile 10815439

3700 Washington St Ste A, Hollywood, FL 33021

Open in the dashboard

General payments

$4,833

220 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandra Castillo of Hollywood, FL is reported in the CMS Open Payments database as having received $4,833 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,305 62
2024 General $1,525 74
2023 General $1,141 53
2022 General $824 28
2021 General $38 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandra Castillo
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Alexandra Castillo were reported at $1,305. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Alexandra Castillo Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $38 $135 $40–$426 $132
2022 $824 $152 $48–$470 $149
2023 $1,141 $166 $54–$529 $160
2024 $1,525 $173 $55–$556 $164
2025 $1,305 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $770 26 payments
  2. Merck Sharp & Dohme Corporation $679 34 payments
  3. Mallinckrodt Hospital Products Inc. $504 23 payments
  4. Pfizer Inc. $480 26 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $289 16 payments
  6. Novo Nordisk Inc $256 11 payments
  7. Boston Scientific Corporation $244 9 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $236 11 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $233 13 payments
  10. Janssen Pharmaceuticals, Inc $217 13 payments
  11. Other $923 38 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,819 219 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. VERQUVO Cardiovascular $889 45 payments
  2. FARXIGA $770 26 payments
  3. ACTHAR $504 23 payments
  4. VYNDAQEL $355 19 payments
  5. LifeVest $233 13 payments
  6. Ozempic $217 9 payments
  7. XARELTO $217 13 payments
  8. VERQUVO Cardiovascular $202 11 payments
  9. JARDIANCE $195 11 payments
  10. Kerendia $184 9 payments
  11. Other $1,657 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record